scholarly journals Field evaluations and in vitro sensitivity of Microdochium nivale to succinate dehydrogenase (SDHI) fungicides

itsrj ◽  
2021 ◽  
Author(s):  
Kurt Hockemeyer ◽  
Paul L. Koch
Keyword(s):  
Succinate Dehydrogenase ◽  
Microdochium Nivale ◽  
In Vitro Sensitivity

scholarly journals Resistance of Sclerotinia homoeocarpa Field Isolates to Succinate Dehydrogenase Inhibitor Fungicides

Plant Disease ◽  
2018 ◽  
Vol 102 (12) ◽  
pp. 2625-2631 ◽  
Author(s):  
James T. Popko ◽  
Hyunkyu Sang ◽  
Jaemin Lee ◽  
Toshihiko Yamada ◽  
Yoichiro Hoshino ◽  
...  
Keyword(s):  
Amino Acid ◽  
Sequence Analysis ◽  
Succinate Dehydrogenase ◽  
Amino Acid Substitution ◽  
Silent Mutation ◽  
Sclerotinia Homoeocarpa ◽  
Subunit Gene ◽  
In Vitro Sensitivity ◽  
Succinate Dehydrogenase Inhibitor

Sclerotinia homoeocarpa isolates were collected from golf courses in Japan and the United States (2016–2017). Japan isolates were collected during a monitoring study and the U.S. isolates were collected due to field failure. Five succinate dehydrogenase inhibitor (SDHI) active ingredients (boscalid, fluopyram, fluxapyroxad, isofetamid, and penthiopyrad) were examined using in vitro sensitivity assays to determine cross-resistance. Sequence analysis revealed a point mutation leading to an amino acid substitution (H267Y) and a silent mutation (CTT to CTC) at codon 181 in the SdhB subunit gene. Isolates with the B-H267Y (n = 10) mutation were resistant to boscalid and penthiopyrad and had increased sensitivity to fluopyram. SdhB silent mutation 181C>T isolates (n = 2) were resistant to boscalid, isofetamid, and penthiopyrad. Sequence analysis revealed 3 mutations leading to an amino acid substitution (G91R, n = 5; G150R, n = 1; G159W, n = 1) in the SdhC subunit gene. Isolates harboring the SdhC (G91R or G150R) mutations were resistant to boscalid, fluxapyroxad, isofetamid, and penthiopyrad. A genetic transformation system was used to generate mutants from a SDHI sensitive isolate to confirm the B-H267Y and C-G91R mutations were direct determinants of SDHI resistance and associated with in vitro sensitivity assay results.

scholarly journals Four years’ monitoring of in vitro sensitivity and candidate molecular markers of resistance of Plasmodium falciparum to artesunate-mefloquine combination in the Thai-Myanmar border

2014 ◽  
Vol 13 (1) ◽  
pp. 23 ◽  
Author(s):  
Papichaya Phompradit ◽  
Poonuch Muhamad ◽  
Raewadee Wisedpanichkij ◽  
Wanna Chaijaroenkul ◽  
Kesara Na-Bangchang
Keyword(s):  
Plasmodium Falciparum ◽  
Molecular Markers ◽  
In Vitro Sensitivity

In Vitro Sensitivity of Probiotics to Human Pancreatic Juice

2008 ◽  
Vol 42 ◽  
pp. S170-S173 ◽  
Author(s):  
Mario Del Piano ◽  
Paolo Strozzi ◽  
Michela Barba ◽  
Serena Allesina ◽  
Francesca Deidda ◽  
...  
Keyword(s):  
Pancreatic Juice ◽  
In Vitro Sensitivity

Functional precision medicine in colorectal cancer based on patient-derived tumoroids and in-vitro sensitivity drug testing.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e15567-e15567
Author(s):  
Lars Henrik Jensen ◽  
Anders Kristian Moeller Jakobsen ◽  
Birgitte Mayland Havelund ◽  
Cecilie Abildgaard ◽  
Chris Vagn-Hansen ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Clinical Trial ◽  
Primary Endpoint ◽  
Drug Testing ◽  
Progression Free Survival ◽  
Patient Specific ◽  
Precision Oncology ◽  
Sensitivity Testing ◽  
In Vitro Sensitivity

e15567 Background: Precision oncology based on in-vitro, functional assays has potential advantages compared to the much more common molecular approach, but the clinical benefit is unknown. We here report the results from the largest prospective interventional clinical trial testing the clinical outcome in colorectal cancer patients treated with drugs showing cytotoxic effect in matched patient-derived tumoroids. Methods: This single-center, phase II trial included patients with metastatic colorectal cancer previously exposed to all standard therapies. Specimens from one to three 18-16 G core needle biopsies were manually dissected, enzymatically treated, cultivated, and incubated to form 3D spherical microtumors, i.e. tumoroids. In the assay for in-vitro sensitivity testing, the tumoroids were challenged with single drugs and combinations thereof to determine patient-specific responses. Using tumoroid screening technology (IndiTreat, 2cureX, Copenhagen, Denmark), results were generated by comparing the sensitivity of the individual patient’s tumoroids with a reference panel from other patients. The testing included standard cytostatics and drugs with proven effect in previous early-phase clinical trials, a total of 15 drugs. The primary endpoint was the fraction of patients with progression-free survival (PFS) at two months. Based on placebo arms in randomized last-line trials, a minimal relevant difference of 20% (20% to 40%) was stated. Using Simon's two-stage design, a sample size of 45 patients was calculated with at least 14 PFS at two months (significance 5%, power 90%). Results: Ninety patients were enrolled from 9/2017 to 9/2020. Biopsies from 82 patients were obtained and sent for tumoroid formation of which 44 (54%, 95% CI 42-65) were successful and at least one treatment was suggested. Thirty-four patients initiated treatment according to the response obtained in the drug assays within a median of 51 days from inclusion (IQR 39-63). The primary endpoint, PFS at two months, was met in 17 of 34 patients (50%, 95%CI 32-68). There were no radiological responses. Median PFS was 81 days (95% CI 51-112) and median OS was 189 days (95% CI 103-277). Conclusions: Precision oncology using a functional approach with patient-derived tumoroids and in-vitro drug sensitivity testing seems feasible. The approach is limited by the fraction of patients with successful tumoroid development. The primary endpoint was met, as half of the patients were without progression at two months. Further clinical studies are justified. Clinical trial information: NCT03251612.

scholarly journals ATP7B expression is associated with in vitro sensitivity to cisplatin in non-small cell lung cancer

2010 ◽  
Vol 1 (2) ◽  
pp. 279-282 ◽  
Author(s):  
YOSHIMASA INOUE ◽  
HOZUMI MATSUMOTO ◽  
SHUNSUKE YAMADA ◽  
KENJI KAWAI ◽  
HIROSHI SUEMIZU ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
In Vitro Sensitivity

Study Of The In-Vitro Sensitivity Of Meningococci And Its Implications In Prophylaxis

1973 ◽  
Vol 28 (5) ◽  
pp. 281-286
Author(s):  
E. Yourassowsky ◽  
E. Schoutens ◽  
M.P. Vanderlinden
Keyword(s):  
In Vitro Sensitivity
Sign in / Sign up

Export Citation Format

Share Document